Korea Investment CORP Grows Position in Alnylam Pharmaceuticals, Inc. $ALNY

Korea Investment CORP raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,855 shares of the biopharmaceutical company’s stock after purchasing an additional 5,096 shares during the quarter. Korea Investment CORP’s holdings in Alnylam Pharmaceuticals were worth $36,149,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after acquiring an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.3% in the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.9% during the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock worth $584,957,000 after purchasing an additional 33,411 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 78,328 shares of company stock worth $35,705,793. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on ALNY. JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a report on Monday, October 13th. Royal Bank Of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Piper Sandler reissued an “overweight” rating and set a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Oppenheimer restated an “outperform” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $451.27 on Friday. The firm has a fifty day moving average price of $455.81 and a 200 day moving average price of $395.84. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a market cap of $59.62 billion, a P/E ratio of -182.70 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.